Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HSCEI June 2026 Index Rebalance: Pre-Implementation Update

HSCEI Index Rebalance: March 2026 Post-Event Review

HSCEI Index Rebalance: Historical Patterns & Mar '25 Event Analysis

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>Hang Seng announced Hansoh Pharma and Akeso as ADDs, and Sunny Optical and Haier Smart Home as DELETEs, effective 8 Jun 2026.</li>
<li>Our 23 Apr forecast called both DELETEs and Hansoh Pharma, but WuXi Biologics was not announced and Akeso was not in the formal slate.</li>
<li>Both ADD names fell through pre-announcement window and entered the bridge window with negative pre-announcement returns, below the historical ADD pre-announcement return.</li>
</ul>


Hang Seng announced Hansoh Pharma and Akeso as ADDs, and Sunny Optical and Haier Smart Home as DELETEs, effective 8 Jun 2026.
Our 23 Apr forecast called both DELETEs and Hansoh Pharma, but WuXi Biologics was not announced and Akeso was not in the formal slate.
Both ADD names fell through pre-announcement window and entered the bridge window with negative pre-announcement returns, below the historical ADD pre-announcement return.


HSCEI June 2026 Index Rebalance: Post-Announcement Positioning

Hansoh Pharmaceutical

HSCEI June 2026 Index Rebalance: Post-Announcement Positioning